File downloaded on 2026-11-09
Source URL: https://medicines.health.europa.eu/veterinary/en/600000034592

Calcibel 240/60/60 mg/ml solution for infusion for horses, cattle, sheep, goats and pigs

Authorised

- Boric acid
- Calcium gluconate
- Magnesium chloride hexahydrate

Product identification

Medicine name:
Calcibel 240/60/60 mg/ml solution for infusion for horses, cattle, sheep, goats and pigs

Active substance:
Boric acid
Calcium gluconate
Magnesium chloride hexahydrate

Target species:
Cattle
Sheep
Horse
Pig
Goat

Route of administration:
Intravenous use

Product details

Active substance and strength:
Boric acid
60.00 milligram(s) / 1.00 millilitre(s)

Calcium gluconate
240.00 milligram(s) / 1.00 millilitre(s)

Magnesium chloride hexahydrate
60.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for infusion

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA12AX

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Denmark

Available in:
Denmark

Package description:
Bottle for infusion made of polypropylene with scaling, closures made of bromobutyl rubber stopper, aluminium caps with tear-off. Pack size 1 x 500 ml.
Bottle for infusion made of polypropylene with scaling, closures made of bromobutyl rubber stopper, aluminium caps with tear-off. Pack size 12 x 500 ml.
Bottle for infusion made of polypropylene with scaling, closures made of bromobutyl rubber stopper, aluminium caps with tear-off. Pack size 6 x 500 ml.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Bela-Pharm GmbH & Co. KG

Marketing authorisation date:
23/05/2016

Manufacturing sites for batch release:
Bela-Pharm GmbH & Co. KG

Responsible authority:
Danish Medicines Agency

Authorisation number:
55682

Date of authorisation status change:
23/05/2016

Reference member state:
Netherlands

Procedure number:
NL/V/0197/001

Concerned member states:
Austria Croatia Cyprus Czechia Denmark Finland Greece Hungary Ireland Poland Portugal Romania Slovakia Slovenia Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.